Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

US Patent 10028911 · Granted Jul 24, 2018

Estimated economic value: $20,455,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Gateline mask design for removing sacrificial gateline polysilicon within stair 2025
Bupivacaine multivesicular liposome formulations and uses thereof2025
Multivesicular liposome formulations of dexamethasone2025
Reagents and methods for tetrazine synthesis2023
Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits,2023
Manufacturing of bupivacaine multivesicular liposomes2022
Manufacturing of bupivacaine multivesicular liposomes2022
Manufacturing of bupivacaine multivesicular liposomes2022
Manufacturing of bupivacaine multivesicular liposomes2022
Manufacturing of bupivacaine multivesicular liposomes2021
Manufacturing of bupivacaine multivesicular liposomes2021
Zinc meloxicam complex microparticle multivesicular liposome formulations and pr2021